# US 10,765,627 B2 · Immunogenic composition against Campylobacter jejuni

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,627 B2
- Document ID: US10765627B2
- Status: Granted
- Kind: B2
- Application number: 16/438,743
- Filed: 2019-06-12
- Published: 2019-11-07
- Granted: 2020-09-08
- Earliest claimed: 2005-09-21
- Assignees: The United States of America as represented by the Secretary of the Navy
- Applicants: United States of America as Represented by the Secretary of the Navy
- Inventors: Patricia Guerry; Mario Artur Monteiro
- Web page: https://patentgrep.com/patent/US10765627B2

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 39/105: {Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter}
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.

## Claims

### Claim 1

A polysaccharide antigen for inducing an immune response against Campylobacter jejuni, said polysaccharide antigen comprising an isolated Campylobacter jejuni capsule polysaccharide from a Campylobacter jejuni strain linked to form a repeating polysaccharide polymer comprising 2 or more of said capsule polysaccharides, wherein said Campylobacter jejuni strain is selected from the group consisting of: HS4, HS5, HS4/13/64, and HS50, wherein said polysaccharide antigens do not contain Campylobacter jejuni lipooligosaccharide structures associated with Guillain Barré Syndrome, wherein said polysaccharide polymer is conjugated to a protein carrier, wherein the structure of HS4 is →3)-L-β-D-ido-Hep-(1→4)-β-D-GlcNAc-(1→, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep, wherein the structure of HS4/13/64 is [→3)-6d-β-D-ido-Hep-(1→4)-β-D-GlcNAc-(1→]n, with non-stoichiometric MeOPN at C-2 and/or C-7 of 6d-ido-Hep, wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100, and wherein the structure of HS5 is selected from the group consisting of

### Claim 2 (depends on 1)

The polysaccharide antigen of claim 1, wherein the structure of HS50 is selected from the group consisting of [→3)-L-β-D-ido-Hep(1→4)-β-D-Glc-(1→]n, with non-stoichiometric MeOPN at C-4 of LD-ido-Hep, and [→3-6d-β-D-ido-Hep-(1→4)-β-D-Glc-(1→]n, with non-stoichiometric McOPN at C-7 of 6d-ido-Hep; and wherein the number of repeats of a capsule polysaccharide “n” is 1 to 100.

### Claim 3 (depends on 1, 2)

The polysaccharide antigen of claim 1 or 2 wherein said protein carrier is CRM197.

### Claim 4 (depends on 1, 2)

A method of immunizing against C. jejuni strains HS4, HS13, HS4/13/64 and HS50 comprising administering to a subject in need thereof one or more antigens, wherein each of said one or more antigens comprises the polysaccharide antigen of claim 1 or claim 2.

### Claim 5 (depends on 4)

The method of claim 4 wherein said protein carrier is CRM197.

### Claim 6 (depends on 4)

The method of claim 4 wherein said method further comprises administering one or more adjuvants.

### Claim 7 (depends on 6)

The method of claim 6 wherein said adjuvant is selected from the group consisting of LTR192G, aluminum hydroxide, RC529, QS21, oligodeoxynucleotides (ODN), and aluminum phosphate.

### Claim 8 (depends on 7)

The method of claim 7, wherein said oligodeoxynucleotide (ODN) is a CpG-containing oligodeoxynucleotide.